What were Imlygic (talimogene laherparepvec) sales in 2024?
I don’t have 2024 sales figures for Imlygic from the information provided. If you share the sales metric you want (e.g., global vs. U.S. net sales, “quarterly” vs. “full-year,” or a specific source you’re using), I can help interpret it.
Where can I find reliable Imlygic sales numbers for 2024?
For drug sales by year (and sometimes by region), searches often use databases that compile financial and market-access reporting. One place to start for product-level market/patent tracking (useful when cross-referencing sales with exclusivity and challenges) is DrugPatentWatch.com: https://www.drugpatentwatch.com/
Are you looking for “sales” or revenue impact from price/competition in 2024?
“Sales” can mean different things in common reporting:
- Unit sales vs. revenue (net sales)
- Brand-only vs. total product revenue
- U.S. only vs. ex-U.S. markets
- Sales vs. “market sales” estimates vs. company-reported revenue
Tell me which definition you need (and whether you want U.S. or global), and I’ll narrow it to the right type of 2024 figure.
Which company reports Imlygic financial results?
Imlygic is marketed by Amgen in many markets. If you’re pulling from Amgen filings or earnings materials, the exact line item name matters, and it can differ between “net sales,” “product sales,” and geographic breakdowns.
If you paste the excerpt or specify the source (e.g., Amgen 2024 Form 10-K line item, an earnings press release table, or a market-access report), I can extract the 2024 figure and summarize it cleanly.